



SOUTHERN CALIFORNIA REGIONAL COMMUNITY OF PRACTICE TO END TB

Wednesday, April 23, 2025 12:00PM - 1:30PM PDT



12:00 – 12:05	Welcome and introductions	Parveen Kaur, MD Clinical Lead Southern CA CoP to End TB	Melissa Zhang TB Control Program Analyst Los Angeles County Department of Public Health
12:05 – 12:20	Why TB prevention?	Parveen Kaur, MD Clinical Lead Southern CA CoP to End TB	
12:20 – 12:35	Overview of tuberculosis epidemiology statewide and in Los Angeles County	Katya Salcedo, MPH Epidemiologist TB Free CA, California Department of Public Health	Julie Higashi, MD PhD TB Control Program Director Los Angeles County Department of Public Health
12:35 – 12:55	The San Diego TBEI Community of Practice model: successes and lessons learned	Catherine Bender, MPH TB Elimination Initiative Director San Diego County TB Control and Refugee Health Branch	
12:55 – 1:10	Overview on school testing requirements	Julie Higashi, MD PhD TB Control Program Director Los Angeles County Department of Public Health	
1:10 – 1:30	Discussion session and meeting closure	Parveen Kaur, MD Clinical Lead Southern CA CoP to End TB	Melissa Zhang TB Control Program Analyst Los Angeles County Department of Public Health



Why TB Prevention?

Parveen Kaur, MD

Clinical Lead, Southern CA Regional CoP to End TB TB Control Program Los Angeles County Department of Public Health Acting Health Officer, TB Controller City of Pasadena Public Health Department





Tuberculosis is the top infectious killer in the world 1.25 million in 2023



1.5 MILLION* **PEOPLE DIED FROM TB**

INCLUDING 251 000 PEOPLE





Tuberculosis resurges as top infectious disease killer

29 October 2024 News release Washington D.C., USA

- The World Health Organization (WHO) published a new report on tuberculosis revealing that approximately 8.2 million people were newly diagnosed with TB in 2023 – the highest number recorded since WHO began global TB monitoring in 1995. This represents a notable increase from 7.5 million reported in 2022, placing TB again as the leading infectious disease killer in 2023, surpassing COVID-19.
- "The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.



What is tuberculosis (TB)?

- TB is a communicable disease caused by a bacterium called *Mycobacterium tuberculosis*
- Primary site of infection is the lungs but can disseminate to any part of the body including spine and brain
- TB spreads through airborne transmission
- Those who have been infected, but are not sick, have latent tuberculosis infection (LTBI) or simply TB Infection





TB Infection (Latent, LTBI)	TB
Bacilli persist in non-replicating form controlled by immune system	Ac
TST/IGRA usually positive	TST/
CXR usually normal	
AFB Sputum smears / cultures negative	AFB
NO symptoms	
NOT infectious	(exc



B Disease (Active)

Actively multiplying bacilli

T/IGRA positive or negative

CXR usually abnormal

B Sputum smears / cultures usually positive

Usually symptomatic

Can be infectious (ceptions: extrapulmonary)

Risk of TB Infection and TB Disease

After Airborne exposure to *Mtb*:

- **5-10%** develop primary TB disease
- **90-95%** of those who have primary infection will develop LTBI
- Those with LTBI have ~10% lifetime risk of progressing to active TB disease (Higher with immunocompromising conditions, kidney disease and DM)

Treatment reduces risk of progression ~90%



Why should we focus on TB prevention?





Active TB is only the "tip of the iceberg"

2100 people had TB disease in CA in 2024

More than **2 million** Californians have LTBI





Millions of people in the U.S. have Iatent TB infection. Without treatment, they are at risk for developing TB disease.

USA

C

U.S. Department of leadth and Haman Services Context for Disease Context and Presentan www.cdc.gov/tb





PREVENTABLE with LTBI testing and treatment



Awareness and treatment of LTBI is low



estimated persons in had LTBI in 2024



of cases with active TB disease started with LTBI... meaning they could have been prevented with testing and treatment of LTBI

TB has tragic consequences



• 1 i

Death

- 1 in 6 die within five years of diagnosis
- 10 -13% do not survive treatment





Hospitalization

•2x expensive and 4x longer than hospitalizations for other conditions



Pascopella, Open Forum Infect Dis, 2014; Lee-Rodriguez JAMA Netw Open. 2020 Hoger, Int J Tuberc Lung Dis, 2014; Shuldiner, Int J Tuberc Lung Dis, 2015; Miller, Am J Public Health. 2015; Duque-Silva, J Ped Inf Dis Soc, 2018 Source: California TB Elimination Action Plan 2021 - 2025



Disability

After treatment, impaired lung function and shorter life expectancy
>80% of children with CNS TB die or permanently disabled

Cost

Catastrophic costs to patients and families
>\$265 million in direct and societal costs in California in 2023

BCG vaccine

- Currently, there is only one licensed vaccine against TB, Bacillus Calmette-Guérin (BCG).
- Despite its protective efficacy against TB in children with severe disseminated TB disease
 - BCG has failed to protect adults against pulmonary TB
 - Lacks therapeutic value and
 - Can cause complications in immunocompromised individuals.
- Due to the variable efficacy of the BCG vaccine against pulmonary TB; the low overall risk of infection with MTB, BCG vaccination is not generally recommended in the **United States**





Why address LTBI in the US?

- Lifetime risk of progressing to TB ~10%
 - Higher in certain risk groups
 - Treatment reduces risk of progression ~90%
- TB has tragic consequences: death, disability, hospitalization
- No effective TB vaccine (treatment = prevention)
- Protects individuals, families and the community
- TB prevention is significantly cheaper than treating TB disease
 - TB prevention = **\$857/person**
 - Treating TB disease = \$43,900/person (~50X cheaper to prevent TB than to treat TB)



"Every case of reactivation TB disease should be considered a missed opportunity for prevention"





Source: https://www.cdc.gov/tb/media/Stop_TB_poster_English.pdf

We have the test. We have the meds. What are the challenges?

Source: https://www.cdc.gov/tb/publications/infographic/images/health-care-setting/TB_FB_5_1200x630.jpg





Barriers to TB Prevention

Patient

- Patient feels well
- Perception of risk: uncertain and not urgent
- Worried about medicine side effects

Provider

- Not considered important clinical problem
- Unclear who to test/treat (guidelines are confusing)
- Suboptimal tests/many treatment options

System

Organizational issues: Not a HEDIS measure; LTBI is not notifiable. EMR issues



California TB Screening Law (AB 2132)

Bill sponsored by CTCA Coalition for a TB Free California took effect as law on January 1, 2025

- Requires adult patients receiving primary care services to be offered a TB test if risk factors are identified.
- If patient's health insurance covers it, the patient should be followed by provision or referral for appropriate follow-up care.





AB 2132 - New CA TB Screening Law

- Focuses on tuberculosis screening and follow-up care in Primary care, aiming to improve public health.
- Effort to implement "Best Practice" to set expectations for Primary care.
- Sets a standard for TB care in the Care Cascade.
- Highlights additional training opportunities for the prevention of latent tuberculosis infection (LTBI).

Is an opportunity to accelerate TB elimination



LTBI cascade of care – pathway to prevention







Retain patient in care and document treatment completion Check appropriate risk factor boxes below.

TB infection testing is recommended if any of the 4 boxes below are checked.

If TB infection test result is positive and active TB disease is ruled out, TB infection treatment is recommended.

Birth, travel, or residence for at least 1 month or frequent border crossing in a country with an elevated TB rate

- Includes countries other than the United States, Canada, Australia, New Zealand, or Western and Northern European countries
- If resources require prioritization within this group, prioritize patients with at least one medical risk for progression (see Fact Sheet for list)
- Interferon Gamma Release Assay is preferred over Tuberculin Skin Test f or non-U.S.-born persons ≥ 2 years old

Immunosuppression, current or planned

HIV infection, organ transplant recipient, treated with TNF-alpha antagonist (e.g., infliximab, etanercept, others), steroids equivalent of prednisone \geq 15 mg/day for \geq 1 month) or other immunosuppressive medication

Close contact to someone with infectious TB disease at any time

The Centers for Disease Control and Prevention indicates that the evaluation of contacts and treatment of infected contacts is an important component of the U.S. strategy for TB elimination

History of homelessness or incarceration, current or past

The U.S. Preventive Service Task Force (USPSTF) recommends screening populations at increased risk for TB infection based on increased risk of exposure including persons who have lived in high-risk congregate settings (e.g. homeless shelters and correctional facilities)



Community of Practice for care improvement and more!

- CoPs in healthcare are usually aimed at improving clinical outcomes or developing a skill, though there may be additional aims such as workforce or patient engagement
- Published studies of CoPs have shown them to be effective at achieving aims ranging from improved clinical guideline adherence and decreased hospital referrals to decreased stress and a sense of empowerment among participants







Slide credit: Susannah Graves A systematic review. PLoS One. 2023; 18(10): e0292343

Summary

- TB is serious increased hospitalization, disability, mortality, and societal costs.
- TB is curable... It is also **Preventable**!
- We have the tools to detect TB infection, medications to treat it and thus prevent progression to TB disease

Identifying and treating persons with TB infection (LTBI) is the most promising tool to prevent TB disease.

- New California TB screening law (AB 2132) establishes best practices towards TB screening and elimination.
- New initiative Southern CA Regional Community of Practice to End TB established to accelerate TB elimination in Southern California.



Southern CA Regional Community of Practice to End TB

- The Southern CA Regional Community of Practice to End TB is established as a platform to focus efforts to prevent TB.
- Modeled after successful TB elimination efforts in both San Diego County and the Bay Area.
- Space for discussions, problem solving to implement and accelerate TB elimination in our region.
- This initiative aims to bring together healthcare providers, clinics, healthcare systems, and public health agencies to collaborate on scaling up LTBI diagnosis and treatment towards TB Elimination in Southern California.



Questions





Epidemiology of Tuberculosis (TB) in California, 2024

Southern California, Community of Practice Katya Salcedo, Epidemiologist CDPH, TB Control Branch April 23, 2025 katya.salcedo@@cdph.ca.gov



2,100 Californians with TB in 2024 California, 2012–2024



Source: Reported Verified Cases of Tuberculosis (RVCT) CDC Provisional 2024 TB data, U.S.

Confidential - Low

National Rate: 3.0

CA Rate: 5.3

More people with TB are dying Death before or during TB treatment, California



CDPH Source: Reported Verified Cases of Tuberculosis (RVCT)

Confidential - Low

Slide credit: Melissa Ehman

People born outside the U.S. bear the largest burden of TB

Birthplace of Persons with TB Disease, California, 2024





Confidential - Low

Marked disparities:

TB rate and rate ratio, California 2024





Source: Reported Verified Cases of Tuberculosis (RVCT) Slide credit: Pennan Barry

Confidential - Low

The TB rate for non-U.S.-born Asians is 60 times higher than the TB rate of White U.S.-born persons

Rate ratios comparing non-U.S.-born by race & ethnicity to U.S.-born white persons

TB is not evenly distributed in all CA counties

Case number (rate per 100,000)

	San Diego	Contra Costa 59	Long Beach 35
	247 (7.5)	San Bernardino 72	Ventura 36 San Joaquin 41
		Riverside 84	Fresno 52
	Los Angeles 542 (5.9)	Alameda 119 (7.8)	Sacro 110
N=45		Orange 166 (5.3)	

Source: Reported Verified Cases of Tuberculosis (RVCT)

Confidential - Low



Most People with TB have been U.S. residents for many years - Years in U.S. at TB diagnosis California, 2020-2024



Source: Reported Verified Cases of Tuberculosis (RVCT)

Confidential - Low

Slide credit: Pennan Barry

More than 30% of people with TB had diabetes or another reported comorbidity General CA Pop, Percentage of PWTB by select risks, 2015-2024 2023* 11.8% Diabetes 30% Percentage 20% 10% mmunosupression ESRD alpha Rx Post transplant 0%



Confidential - Low

2024

What about Latent TB Infection (LTBI)?

- Approximately 25% of the world's population has LTBI
- Approx. 13 million people in the U.S. have LTBI
 - In California, more than 2 million people have LTBI (approx. 6% of the population)
 - Approx. 1.8 million of them grew up outside of the U.S.
 - Only about 20% know they have LTBI, and most have not been treated



LTBI

25%

Most TB in California arises from progression of untreated LTBI



Progression of LTBI 83%



Confidential - Low



Slide credit: Pennan Barry
Summary

In California:

- TB case count remains stagnant
- TB deaths are increasing
- People born outside the U.S. bear the largest burden of TB
- There are marked disparities by race, ethnicity, and place of birth
- Comorbidities that increase risk and complicate treatment are common

TB can be prevented with LTBI treatment!



Visit the California Department of Public Health website.



Epidemiology of Tuberculosis (TB) in Los Angeles County, CA, 2024

Epidemiology & Research Unit Tuberculosis Control Program April 23, 2025 Julie Higashi, MD PhD







Acknowledgement



WORLD TB DAY MARCH 24

- the clinicians, nurses, and public health staff in the County clinics, districts, and health centers;
- the Public Health Laboratory;
- Public Health Information Services;
- and various community-based and private partners in the successful control and elimination of tuberculosis.





The information presented here represents the dedication and work of everyone in the Tuberculosis Control Program:

TB disease incidents in Los Angeles County (LAC) 1970-2024

of TB Disease Incidents



Year of TB Confirmation

Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data and initial case count reported, updated March 13, 2025.







Mortality due to any cause among TB disease incidents, 2000-2024



Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data, updated March 13, 2025.







*2024 mortality data are preliminary

Tuberculosis Disease Incidents per 100,000 Population

Jurisdiction	2017-2019 median*	2020	2021	2022	2023	2024
Los Angeles County	5.2	4.5	4.7	5.3	5.5	5.5
California ¹	5.3	4.3	4.4	4.7	5.4	5.4
United States ²	2.8	2.2	2.4	2.5	2.9	3.0

1.https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/TB-Disease-Data.aspx 2.<u>https://www.cdc.gov/tb/statistics/default.htm</u>

*The median number for 2017-2019 is used to represent the best estimate of the pre-COVID baseline and account for potential outliers.





How do TB disease incidents occur in Los Angeles?

7% Importation*

177 of 2,529 cases occurred < 1 year of arrival in U.S. (2020-2024)

~500 Cases Per Year

81% Progression

From TB infection (cases not from importation or recent transmission)

*2024 saw a 22% increase in TB cases occurred < 1 year of arrival vs. 2023 **Preliminary estimate based on CDC number of 2023 recent transmission cases and number of total genotyped cases (not from plausible source case method)





12% Recent Transmission**

TB Disease Incidents: Characteristics and Trends







Nativity status for TB disease incidents, 2004-2024



Includes TB disease incidents with known place of birth. Data exclude TB disease incidents with unknown birthplace. Data exclude Pasadena and Long Beach TB cases and are provisional to change. Based on TRIMS data, updated March 13, 2025.



Percentage of TB Disease Incidents Among Non-U.S.-Born Persons by Years Since Arrival in the United States Prior to Diagnosis, 2024



Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data, updated March 13, 2025.





18%

TB disease incidents by race/ethnicity (counts) 2017-2024



■ 2017-2019 Median ■ 2020 ■ 2021 ■ 2022 ■ 2023 ■ 2024

Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data, updated March 13, 2025.

Note: American Indian/Alaska Native and Native Hawaiian/Pacific Islander categories not shown on the graph. <5 TB disease incidents of American Indian/Alaskan Native race/ethnicity in 2017-2024.

<5 TB disease incidents of Native Hawaiian/Pacific Islander race/ethnicity in 2017-2024.



Pediatric (0-14 years of age) TB disease incidents, 2017-2024

2024 pediatric TB incidents were **56% LOWER** than in 2023.

25 Year 21 20 # of TB disease incidents051 16 2017-2019 14 Median 2020 10 2021 7 7 2022 5 2023 0 2024 0-14 years of age 2017-2019 Median ■ 2020 ■ 2021 ■ 2022 ■ 2023 ■ 2024

Note: Pediatric age group defined by TB surveillance conventions, not for clinical purposes.

Microbiologically confirmations include: positive culture, positive NAAT, positive smear/tissue.

Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data and initial case count reported, updated March 13, 2025.





Pediatric TB disease incident characteristics

	% Microbiologically Confirmed	% Hispanic race/ethnicity
9	47%	82%
	70%	50%
	29%	71%
	43%	81%
	63%	88%
	57%	86%

Pediatric (0-14 years of age) TB Cases by Nativity, 2017-2024

■ US-born ■ Non-US-born



Note: Pediatric age group defined by TB surveillance conventions, not for clinical purposes.

Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data and initial case count reported, updated March 13, 2025.





Pediatric (0-14 years of age) TB Cases by Race/Ethnicity, 2017-2024

■ Hispanic ■ Other Race/Ethnicity



Note: Pediatric age group defined by TB surveillance conventions, not for clinical purposes. Data exclude Pasadena and Long Beach TB disease incidents and are provisional to change. Based on TRIMS data and initial case count reported, updated March 13, 2025.







- TB disease incidents in Los Angeles County and California have remained stable at pre-COVID levels for the second year in a row
- TB disease incidents in the Hispanic population of LA County have increased since 2020-2022
- After an abrupt increase in pediatric disease incidents in 2022, an indicator of local transmission, reported incidents in the last two years have decreased, and are concentrated in the Hispanic population
- TB mortality remains higher than pre-COVID, with the third consecutive annual increase in number of TB deaths.
- Scaling up diagnosis and treatment of TB infection is critical for maintaining progress toward TB elimination after the disruption of the COVID-19 pandemic







Questions









SAN DIEGO COUNTY **TB ELIMINATION INITIATIVE (TBEI) COMMUNITY OF PRACTICE**

April 23, 2025

Catherine Bender, MPH

TBEI Program Coordinator, County of San Diego TB and Refugee Health Branch







San Diego County TB Elimination Initiative (TBEI)

What is the TBEI?

A Board of Supervisors approved, **public-private partnership**, launched in January 2020, to build a coordinated tuberculosis (TB) elimination framework in San Diego County.







TBEI Structure



Dr. Richard Garfein, UCSD





TBEI Program Director Catherine Bender, County of San Diego

Schools and Community Outreach Projects

Facilitated by County of San Diego and TBEI Members

TBEI COMMUNITY OF PRACTICE





TBEI Community of Practice

In October 2021, the TBEI formed a **Community of Practice (CoP)** to encourage the development and use of LTBI care cascades by healthcare organizations in the County.

- Latent Tuberculosis Infection (LTBI) care **cascades** describe the proportion of a population that has been screened for infection, received results, referred for diagnosis, evaluated for treatment, and started and completed treatment.
- **Attrition** in the LTBI care cascade highlights opportunities for intervention and provides data to evaluate the impact of quality improvement efforts.
- Many providers lack data, tracking systems, and/or expertise to create and use a LTBI care cascade.







Alsdurf H et al. Lancet ID, 2016

TBEI Community of Practice

The GOAL of the TBEI CoP is to move San Diego County forward in implementing LTBI care cascade best practices.

MEMBERS

Primary care, infectious disease, and pulmonary medicine providers, epidemiologists, quality leads from community clinics, health systems, health plans, universities, and state and local health departments

ROLES

- Educate and encourage wider adoption of LTBI care cascade in 1) healthcare settings throughout the County
- Set individual goals for clinics 2)
- Be early adopters share interventions and report back lessons 3) learned
- Share data from clinic LTBI care cascades 4)
- Encourage EHR enhancement needed to produce a care 5) cascade





TBEI CoP Quarterly Meeting Format

Member and partner presentation(s)

- Patient demographics
- Why they chose to improve LTBI care cascade
- How they achieved buy-in for changes
- How they approached improvement projects (e.g. workgroups established, stakeholders involved)
- **Baseline LTBI data**
- Resulting strategies and interventions to improve LTBI care cascade
- Future plans

Working session – member round robin

- Sharing progress of LTBI care improvement plans and interventions
- Raise questions and barriers for member input into potential solutions
- Share existing and new tools and resources to address barriers







TBEI Community of Practice – Growing Membership

Accomplishments Include:

- Advanced LTBI improvement initiatives at each site
- Expanded capacity to measure LTBI data most members shared LTBI data
- ✓ LTBI Toolkit developed for provider and patient education
- ✓ Provider education implemented across all sites
- ✓ LTBI patient outreach across multiple sites
- ✓ Partnerships with CDPH, TB Free CA, and CDC





- American Pacific Health Foundation
- California Department of Public Health, TB Control
- County of San Diego TB Clinic, Pharmacy, and Behavioral Health Services
- CDC
- Children's Primary Care Medical Group
- Family Health Centers of San Diego
- Father Joe's Villages
- Indian Health Council
- Kaiser Permanente
- La Maestra
- Opsam Health
- San Diego Family Care
- San Ysidro Health
- San Diego American Indian Health Center
- Scripps Health
- Sharp Community Medical Group
- Southern Indian Health Center
- TrueCare
- UCSD Health
- UCSD School of Public Health and School of Medicine
- Vista Community Clinic

TBEI Community of Practice Highlights

Advancing LTBI Improvement Initiatives

CoP members shared enhanced LTBI practices, data and interventions at quarterly meetings during member presentations and round robin, including:

- Provider education (presentations at primary care staff meetings and grand rounds).
- Presentations to quality improvement committees to begin LTBI improvement projects.
- EMR updates (include TB risk assessment at annual visit, provider notifications, treatment completion letters generated through EMR, decision support tools for treatment in EMR, best practice advisory, LTBI registry generated per EMR).
- Testing with IGRA instead of TST for patients at risk.
- Implementing LTBI care coordinators (to limit impact on primary care).
- Provide patient education materials in appropriate languages at primary care visits.
- Enhanced employee TB testing protocols with focus on LTBI treatment.
- Follow-up with women testing positive for LTBI during pregnancy to encourage LTBI treatment post-delivery.
- "All family" LTBI approach reduce individual outreach.







TBEI Community of Practice Highlights

Expanding Capacity for LTBI Care Cascade Measurement

- **Baseline LTBI care cascade** measurement, and resulting interventions shared by 11 provider organizations.
- Many sites sharing ongoing LTBI quarterly measurement and addressing gaps.
- Development of new workgroups to focus on LTBI improvement after LTBI baseline measurement highlighted need for intervention.







TBEI Community of Practice Highlights

Enhancing Provider Education and Outreach

- **TBEI members presented LTBI care cascade education, strategies, and resources** to provider forums reaching over 300 providers in San Diego County each year since 2023
 - Primary care provider forums
 - County healthcare sector meetings
 - Health plan advisory committee meetings
 - In-person TB Prevention Education and Community Engagement Summit (2024)
- World TB Day social media strategies and email messaging to providers
- **TBEI Article** in San Diego Physician Magazine
- **LTBI tools and resources** developed and shared, including:
 - TBEI CoP provider education slide set
 - LTBI toolkit





Lessons Learned

Engaging providers in a CoP helps build momentum and inspire members to focus on their LTBI care cascade.

- Each member organization has different capacity for LTBI measurement and quality improvement strategies.
- It is important for each member to assesses what is in their capacity to create change and best way to secure buy-in. Both incremental and largescale changes make a difference and start the quality improvement process.
- Communication slides assist providers with seeking buy-in and getting started on identifying changes needed.
- Access to EHR tools and template examples encourage provider willingness to explore enhancements.
- Quarterly check-ins sharing member progress helps keep LTBI top of mind amidst other priorities.
- Individual meetings including provider education and learning about existing practices are helpful to engage new members.
- Providers need training to collect and use data for cascades.





Questions?



Thank you!

Catherine.Bender@sdcounty.ca.gov





Overview of K-12 School Entry Testing Requirements

Julie Higashi, MD PhD Director, Tuberculosis Control Program April 22, 2025





Recent Guidance on K-12 School Entry TB Screening in California

CTCA Position on TB Evaluation of School-Age Children

2024 Update

Summary

The major benefits for screening are:

- 1. identifying students who would benefit from LTBI treatment
- 2. encouraging screening of families in which children have LTBI and
- 3. providing information about tuberculosis and promoting LTBI treatment

Summary of rationale for update to CTCA guidance regarding TB screening upon school entry:

A. The TB risk assessment process should promote equity for all students by encouraging families to engage with a primary care medical home for screening while not excluding



Please answer the poll question on screen: Are you currently doing universal or risk-based testing?



K-12 School Entry Screening is a TB Elimination Activity

- K-12 school entry screening is determined by the local health officer California Health and Safety Code 121475-121520
- Promotes health equity for children from at risk populations by supporting linkage to primary care and TB care
- Potential for higher impact in high morbidity areas
 - Identify students who would benefit from TB infection treatment
 - Encourage screening of families in which children have TB infection
 - Provide information about tuberculosis and promoting TB infection treatment
 - Provides baseline testing results for contact investigations following TB exposures in educational settings*



Please answer the poll question on screen: Have you had a TB exposure or contact investigation at your school in the last 2 years?



Approach

California Pediatric Tuberculosis Risk Assessment

- A negative tuberculin skin test or interferon gamma release assay does not rule out active TB disease.
- In communities with high rates of TB or households with recent active TB, children might be at higher risk of TB exposure. Consider testing children in households with adults with symptoms of pulmonary TB (e.g. cough >2 weeks, fevers, night sweats).

LTBI testing is recommended if any of the boxes below are checked. Only repeat TB testing if there is a new risk factor since last screening **Birth, travel, or residence** for at least 1 month, or frequent border crossing in a country with an elevated TB rate* Interferon Gamma Release Assay (IGRA) is preferred over Tuberculin Skin Test (TST), especially for non-U.S.born persons □ Immunosuppression, current or planned HIV infection, organ transplant recipient, congenital or acquired immune deficiency, or treated with biologic agents including TNF-alpha antagonist (e.g., infliximab, adalimumab, etanercept, others), steroids (equivalent of prednisone ≥2 mg/kg/day, or ≥15 mg/day for ≥2 weeks) or other immunosuppressive medication □ Close contact to someone with infectious TB disease during lifetime Treat for LTBI if LTBI test result is positive and active TB disease is excluded.

- Children can complete risk assessment from 1 year prior to and up to after 90 days post school entry
- If risk identified by provider, TB test is done and if TB test positive, additional evaluation is completed
- No school exclusion if child is asymptomatic


- Shift from universal screening to risk based screening takes resources to establish a clearance process for students with positive TB tests
- If the child has a positive TB test and is asymptomatic, they should not be excluded from school
- If a child has TB risks, a positive TB test and TB symptoms report to local health department

 - Children < 10 years old are not considered to be infectious but should receive clinical care Children > 10 years old should be excluded until medically cleared to return to school



Please answer the poll question on screen: Are you excluding kids from school because they have not finished their **TB** testing?









TB Program Website



Tuberculosis Control Program	Inf
About Us	
News and Updates	
Information for Licensed Providers	
Information for the Public	
Information for Educational and Childcare Settings	
Data & Statistics	
TB Infection Provider Guidance Toolkit	
Coalition to End TB in Los Angeles County	
Strategic Plan	
TB Información en Español (CDC)	





K-12 school entry TB clearance process update

TB Clearance for K-12 Students

Take the <u>Report of Health Exam for School Entry</u> Form to your pediatrician or, if you don't have insurance, take the form to a Healthcare provider

*The TB risk assessment can be completed up to a year prior, or 90 days after, entry to a new school district.

The provider will do a <u>TB Risk Assessment</u> and order a TB skin or blood test and/or chest x-ray, if needed, along with the required physical exam for school entry.

Your provider will sign and complete the Report of Health Examination for School Entry Form after confirming you do not have infectious TB disease, or if needed will direct you to appropriate treatment for TB infection or disease.

Give the signed, completed <u>Report of Health Examination</u> for School Entry Form to your school nurse or other designated school official.

Finished





Take the **Report of Health Exam for <u>School Entry</u>** Form to your pediatrician or, if you don't have insurance, take the form to a Healthcare provider *The TB Clearance process can be completed up to a year prior, or 90 days after entry to a new school district.



- A negative tuberculin skin test or interferon gamma release assay does not rule out active TB disease.
- In communities with high rates of TB or households with recent active TB, children might be at higher risk of TB exposure. Consider testing children in households with adults with symptoms of pulmonary TB (e.g. cough >2 weeks, fevers, night sweats).

LTBI testing is recommended if any of the boxes below are checked. Only repeat TB testing if there is a new risk factor since last screening

Birth, travel, or residence for at least 1 month, or frequent border crossing in a country with an elevated TB rate*

Interferon Gamma Release Assay (IGRA) is preferred over Tuberculin Skin Test (TST), especially for non-U.S.born persons

Immunosuppression, current or planned

HIV infection, organ transplant recipient, congenital or acquired immune deficiency, or treated with biologic agents including TNF-alpha antagonist (e.g., infliximab, adalimumab, etanercept, others), steroids (equivalent of prednisone ≥2 mg/kg/day, or ≥15 mg/day for ≥2 weeks) or other immunosuppressive medication

□ **Close contact** to someone with infectious TB disease during lifetime

Treat for LTBI if LTBI test result is positive and active TB disease is excluded.



Report of Health Examination for School Entry

State of California-Health and Human Services Agency

REPORT OF HEALTH EXAMINATION FOR SCHOOL ENTRY

To protect the health of children, California law requires a health examination on school entry. Please have this report filled out by a health examiner and return it to the school. The school will keep and maintain it as confidential information.

PART I TO BE FILLED OUT BY A PARENT OR GUARDIAN						
CHILD'S NAME—Last	First	Middle		BIRTH DATE-Month/Day/Year		
ADDRESS-Number, Street	City	ZIP code	SCHOOL			

PART II TO BE FILLED OUT BY HEALTH EXAMINER

HEALTH EXAMINATION

NOTE: All tests and evaluations except the blood lead test must be done after the child is 4 years and 3 months of age.

REQUIRED TESTS/EVALUATIONS	DATE (mm/dd/yy)
Health History	JJ
Physical Examination	JJ
Dental Assessment	JJ
Nutritional Assessment	JJ
Developmental Assessment	JJ
Vision Screening	JJ
Audiometric (hearing) Screening	JJ
TB Risk Assessment and Test, if indicated	JJ
Blood Test (for anemia)	JJ
Urine Test	
Blood Lead Test	
Other	J J

IMMUNIZATION RECORD

Note to Examiner: Please give the family a completed or updated yellow California Immunization Record. Note to School: Please record immunization dates on the blue California School Immunization Record (PM 286).

		DATE EA	CH DOSE W/	AS GIVEN	
VACCINE	First	Second	Third	Fourth	Fifth
POLIO (OPV or IPV)					
DtaP/DTP/DT/Td (diphtheria, tetanus, and [acellular] pertussis) OR (tetanus and diphtheria only)					
MMR (measles, mumps, and rubella)					
HIB MENINGITIS (Haemophilus Influenzae B) (Required for child care/preschool only)					
HEPATITIS B					
VARICELLA (Chickenpox)					
OTHER (e.g., TB Test, if indicated)					
OTHER					

PART III ADDITIONAL INFORMATION FROM HEALTH EXAMINER (optional) a	and RELEASE OF HEALTH IN
RESULTS AND RECOMMENDATIONS	I give permission for the health examin check-up with the school as explained in P
Fill out if patient or guardian has signed the release of health information.	Please check this box if you do not wa
Examination shows no condition of concern to school program activities.	
Conditions found in the examination or after further evaluation that are of importance to schooling or physical activity are: (please explain)	
	Signature of parent or guardian
	Name, address, and telephone number of
	Signature of health examiner

If your child is unable to get the school health check-up, call the Child Health and Disability Prevention (CHDP) Program in your local health department. If you do not want your child to have a health check-up, you may sign the waiver form (PM 171 B) found at your child's school.



Department of Health Care Services Child Health and Disability Prevention (CHDP) Program

NFORMATION BY PARENT OR GUARDIAN

iner to share the additional information about the health Part III.

ant the health examiner to fill out Part III.

Date

f health examiner

Date

The provider will do a <u>TB Risk Assessment</u> and order a TB skin or blood test and/or chest x-ray, if needed, along with the required physical exam for school entry.



Report of Health Examination for School Entry

State of California-Health and Human Services Agency

REPORT OF HEALTH EXAMINATION FOR SCHOOL ENTRY

To protect the health of children, California law requires a health examination on school entry. Please have this report filled out by a health examiner and return it to the school. The school will keep and maintain it as confidential information.

CHILD'S NAME—Last	First				Middle			BIRTH DATE-N	fonth/DawYear	
									,	
ADDRESS—Number, Street		City			ZIP code	SCHOOL				
PART II TO BE FILLED OUT BY HE	ALTH EXAMINER									
HEALTH EXAMINATION			IMMUNIZATION RECOR	8D						
NOTE: All tests and evaluations except the must be done after the child is 4 years and			Note to Examiner: Please Note to School: Please	se give the f	family a completed or unization dates on th	r updated yellov e blue Californi	v California I a School Imr	mmunization R nunization Rec	ecord. ord (PM 286).	
REQUIRED TESTS/EVALUATIONS	DATE (mm/dd/yy)						DATE E	ACH DOSE W	AS GIVEN	
Health History	JJ			VACCINE		First	Second	Third	Fourth	Fifth
Physical Examination	JJ		POLIO (OPV or IPV)							
Dental Assessment	//		DtaP/DTP/DT/Td (diph)	theria, tetanu	us, and [acellular]					
Nutritional Assessment	JJ		pertussis) OR (tetanus	and diphther	ria only)					
Developmental Assessment	JJ		MMR (measles, mumps	s, and rubella	a)					
Vision Screening	JJ		HIB MENINGITIS (Hae	mophilus Inf	luenzae B)					1
Audiometric (hearing) Screening	1 1		(Required for child care	/preschool o	inly)					
TB Risk Assessment and Test, if indicated	JJ	>	HEPATITIS B							
Blood Test (for anemia)	JJ		VARICELLA (Chickenp	iox)					-	
Urine Test	JJ		OTHER (e.g., TB Test, if indicated)							
Blood Lead Test Other			OTHER (e.g., TB Test,	ir indicated)						
PART III ADDITIONAL INFORMATIC	ON FROM HEALTH	Examin	IER (optional) a	nd	RELEASE OF H					
RESULTS AND RECOMMENDATIONS				I give per check-up v	mission for the hea with the school as exp	alth examiner plained in Part I	to share the II.	e additional in	formation abo	ut the hea
Fill out if patient or guardian has signed the rel	ease of health informat	ion.			check this box if you	do not want th	e health exa	miner to fill out	Part III	
Examination shows no condition of concern	to school program act	ivities.		L	uncer and box in you		ie riedini eno			
Conditions found in the examination or after physical activity are: (please explain)	r further evaluation that	t are of ir	nportance to schooling or							
				Signatu	re of parent or guardian				Date	
				Name, add	dress, and telephone	number of heal	th examiner			
Chest x ray										
enesexiay										
				Signatu	re of health examiner				Date	

If your child is unable to get the school health check-up, call the Child Health and Disability Prevention (CHDP) Program in your local health department. If you do not want your child to have a health check-up, you may sign the waiver form (PM 171 B) found at your child's school.

PM 171 A (09/07) (Bilingual)

CHDP website: www.dhcs.ca.gov/services/chdp



Department of Health Care Services Child Health and Disability Prevention (CHDP) Program

	DATE EACH DOSE WAS GIVEN							
st	Second	Third	Fourth	Fifth				
				1				
				1				
			1					

Your provider will sign and complete the Report of Health Examination for **School Entry Form after confirming** you do not have infectious TB disease, or if needed will direct you to appropriate treatment for TB infection or disease.



Tuberculosis Clearance Form

This satisfies requirements in the California Education Code, and the California Health and Safety Code. Certificate of Completion of Tuberculosis Risk Assessment and/or Examination

Date of TB risk assessment and/or examination: _____month/___day/____year

First and Last Name of the patient assessed and/or examined:

Date of Birth: _____month/___day/____year

The patient named above has submitted to a pediatric tuberculosis risk assessment. The patient does not have risk factors, or if tuberculosis risk factors were identified, the patient has had a TB skin test (TST) or TB blood test (IGRA), and chest x-ray (CXR) if indicated, and upon exam determined to be free of infectious tuberculosis. The patient is cleared to attend school.





Different Local Health Jurisdiction Policies



Implementation Needs





Interjurisdictional Coordination

Resources for Families Resources for School Districts Resources for Community Providers

- California Tuberculosis Controller's Association
- California Department of Public Health Tuberculosis Control Branch
- Los Angeles County Tuberculosis Control Program
 - Health Education Team
 - Southern California COP Team
 - Contact Investigation Outbreak Team



CALIFORNIA REGIONAL **COMMUNITY OF PRACTICE TO END TB**

GOAL: to foster collaboration and knowledge sharing among providers, clinics, healthcare systems, and other public health agencies to scale up the diagnosis and treatment of TB infection, improve patient outcomes, and strengthen community engagement across Southern California.







COMMUNITY OF PRACTICE TO END TB

Discussion

- What are you hoping to gain from participating in this Community of Practice?
- 2. What barriers to TB prevention have you experienced in your health care setting?
- What are the opportunities for improvement in TB prevention activities 3. in your healthcare setting?
- Are there any tools, resources, or topics that you would like to see 4. addressed through this Community of Practice?







SOUTHERN CALIFORNIA REGIONAL **COMMUNITY OF PRACTICE TO END TB**

Resources

- Thursday, April 24, 2025 from 12:00-1:35PM PST Latent TB Infection (LTBI): **Opportunities for Preventing TB**
 - Free virtual training (with 1.5 CEU/CME's) for CA clinicians and other public health professionals
 - Hosted by TB Free California
- Friday, May 30, 2025 from 9:00-11:00AM PST Preventing TB in Your Clinical Setting
 - Free virtual training (with 1.75 CEU/CME's) for PCPs and other public health professionals
 - Hosted by TB Free California
- Available in May Qiagen trainings to support California TB Screening Law AB 2132
 - CME accredited, on-demand webinar with Dr. Thanassi and Mike Carson, discussing the reason for the law, the benefits to CA communities and best practices
 - CEU accredited, on-demand webinar for RN/NP/PA
 - Medical Assistant educational, recorded presentation on "How and Why" to ask risk screening questions







LATENT TB INFECTION (LTBI): **OPPORTUNITIES FOR PREVENTING TB**

A Free Virtual Training (with 1.5 CEU/CME's) for California Clinicians and Other Public Health Professionals

THURSDAY, APRIL 24TH, 20 12:00-1:35PM PS1



PRESENTED BY SHEREEN KATRAK, MD. MPH KRISTEN WENDORE, MD. MPH ARTMENT OF PUBLIC HEALTH TB CONTROL BRANCH

Did you know?

s in California betwee

Training Objectives

- Identify persons at higher risk for tuberculosis should be tested for TB infection
- Describe and apply how to test for TB infection, including the preferential use of interferon gamma release assay (IGRA) testing for non-U.S.-born persons
- Describe and advise on/facilitate the proper clinica evaluation needed to distinguish latent TB infection (LTB from TB disease
- Describe and advise on/provide the preferred short-cours treatment regimens for LTBI to improve treatmen completion outcomes

This training will be held virtually via Zoom To receive continuing education units, you must pre-register at this link:h s/webinar/register/WN_siJaPemwR6yh7q_bjRUTvg eive an email with the Zoom link and

SOUTHERN CALIFORNIA REGIONAL **COMMUNITY OF PRACTICE TO END TB**

Future meetings

June (date TBD)	Partner presentations: Opportunities for EHR imp LTBI and maternal health
August (date TBD)	TBD
October (date TBD)	Partner presentation: Clinical pharmacy-led LTBI

Topics and presenters subject to change







provement

I clinic model





SOUTHERN CALIFORNIA REGIONAL COMMUNITY OF PRACTICE TO END TB

Thank you!

